专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明申请

WO2011033391A3 METHODS OF TREATING A PATIENT RECEIVING A CARDIAC STENT IMPLANT 审中-公开
标题翻译：治疗接受心脏移植植入物的患者的方法
公开(公告)号：WO2011033391A3
公开(公告)日：2011-05-19
申请号：PCT/IB2010002701
申请日：2010-10-21
申请人： VIRON THERAPEUTICS INC , LUCAS ALEXANDRA R
发明人： LUCAS ALEXANDRA R
IPC分类号： A61K38/16 , A61K38/37
CPC分类号： A61K38/1709 , G01N33/573 , G01N2800/32
摘要： Methods of treating a patient receiving a cardiac stent implant including the steps of: (i) monitoring the circulating level of Tn I or CK-MB in the patient; and (ii) administering SERP-I to the patient in an amount sufficient to prevent the circulating level of Tn I or CK-MB from exceeding a specified threshold for the first 24 hours following implantation are disclosed. A specified value of SERP-I is sufficient for preventing circulating level of Tn I or CK-MB from exceeding a specified threshold during the first 24 hours following implantation. The dosing regime of SERP-I to the patient starting within 24 hours of post-implantation is also disclosed.
摘要翻译：治疗接受心脏支架植入物的患者的方法包括以下步骤：（i）监测患者中Tn I或CK-MB的循环水平; 并且（ii）以足以防止植入后的前24小时内Tn I或CK-MB的循环水平超过规定阈值的量向患者施用SERP-1。在植入后的前24小时内，SERP-1的规定值足以防止Tn I或CK-MB的循环水平超过规定的阈值。还公开了在植入后24小时内从患者开始服用SERP-1的给药方案。

2. 发明申请

WO0246214A3 IMMUNOMODULATORY PROTEIN DERIVED FROM THE YABA MONKEY TUMOR VIRUS 审中-公开
标题翻译：从YABA猴子肿瘤病毒衍生的免疫调节蛋白
公开(公告)号：WO0246214A3
公开(公告)日：2002-09-26
申请号：PCT/CA0101734
申请日：2001-12-04
申请人： VIRON THERAPEUTICS INC , MCFADDEN GRANT , LUCAS ALEXANDRA , LI XING
发明人： MCFADDEN GRANT , LUCAS ALEXANDRA , LI XING
IPC分类号： A01K67/027 , A61K31/7088 , A61K38/00 , A61K48/00 , A61P3/10 , A61P9/00 , A61P9/08 , A61P9/10 , A61P11/06 , A61P13/12 , A61P17/06 , A61P19/02 , A61P25/00 , A61P29/00 , A61P37/02 , A61P37/06 , A61P37/08 , C07H21/04 , C07K14/065 , C07K16/08 , C12N1/15 , C12N1/19 , C12N1/21 , C12N5/10 , C12N7/00 , C12N15/09 , C12N15/86 , C12Q1/02 , C12Q1/68 , C12Q1/70 , G01N33/15 , G01N33/50 , G01N33/53 , G01N33/532 , A61K38/16 , A61P37/00 , C12N15/39 , G01N33/68
CPC分类号： C07K14/005 , A01K2217/05 , A61K38/00 , A61K48/00 , C12N2710/24022
摘要： This invention features a novel secreted viral protein that is isolated from the genome of the poxvirus family, namely, the Yaba Monkey Tumor Virus. The invention also features methods of using the protein, for example, in the treatment of diseases, wherein the protein has an anti-inflammatory and/or immunomodulatory effect when administered in vivo.
摘要翻译：本发明的特征在于从痘病毒家族的基因组即Yaba猴肿瘤病毒中分离的新型分泌的病毒蛋白。本发明还具有使用蛋白质的方法，例如用于治疗疾病，其中当体内施用时蛋白质具有抗炎和/或免疫调节作用。

3. 发明申请

WO0104318A3 MYXOMA VIRUS GENES FOR IMMUNE MODULATION 审中-公开
标题翻译： MYXOMA病毒基因免疫调节
公开(公告)号：WO0104318A3
公开(公告)日：2001-08-09
申请号：PCT/IB0001043
申请日：2000-07-12
申请人： VIRON THERAPEUTICS INC
发明人： MCFADDEN GRANT
IPC分类号： A01K67/027 , A61K31/7088 , A61K35/76 , A61K38/00 , A61K39/00 , A61K45/00 , A61K48/00 , A61P1/04 , A61P1/16 , A61P3/10 , A61P5/14 , A61P7/04 , A61P7/06 , A61P9/10 , A61P11/00 , A61P11/06 , A61P13/12 , A61P17/00 , A61P17/06 , A61P19/02 , A61P21/04 , A61P25/00 , A61P25/28 , A61P29/00 , A61P31/04 , A61P31/18 , A61P35/00 , A61P35/04 , A61P37/02 , A61P37/04 , A61P37/06 , A61P37/08 , A61P43/00 , C07K14/065 , C07K14/52 , C07K14/705 , C07K16/08 , C12N5/10 , C12N15/09 , C12N15/39 , C12Q1/68 , C12R1/91 , G01N33/15 , G01N33/50 , G01N33/53 , G01N33/566 , A61K39/275 , C12N15/11 , G01N33/569
CPC分类号： C07K14/005 , A01K2217/05 , A61K39/00 , A61K48/00 , C12N2710/14143 , C12N2710/24022 , C12N2740/13043
摘要： The present invention provides genes of the viral genus leporipox that encode immunomodulatory proteins. The present invention also provides therapeutic compositions containing these polypeptides and methods for use for treating a variety of inflammatory and autoimmune disorders. In one preferred embodiment, the present invention provides methods for producing the immunomodulatory polypeptides in a substantially pure form. In another preferred embodiment, the invention provides methods for treating individuals diagnosed with autoimmune or inflammatory disorders by gene therapy. In yet another preferred embodiment, the methods and compositions of the present invention may be used to treat cancer. Finally, the invention provides methods to identify and isolate additional leporipox virus immunomodulatory polypeptides.
摘要翻译：本发明提供编码免疫调节蛋白的病毒属leporipox的基因。本发明还提供含有这些多肽的治疗组合物和用于治疗各种炎性和自身免疫性疾病的方法。在一个优选的实施方案中，本发明提供了以基本上纯的形式产生免疫调节多肽的方法。在另一个优选的实施方案中，本发明提供了通过基因治疗来治疗被诊断为自身免疫性或炎症性疾病的个体的方法。在另一优选实施方案中，本发明的方法和组合物可用于治疗癌症。最后，本发明提供鉴定和分离另外的leporipox病毒免疫调节多肽的方法。

4. 发明申请

WO2011033391A2 METHODS OF TREATING A PATIENT RECEIVING A CARDIAC STENT IMPLANT 审中-公开
标题翻译：治疗接受心脏移植植入物的患者的方法
公开(公告)号：WO2011033391A2
公开(公告)日：2011-03-24
申请号：PCT/IB2010/002701
申请日：2010-10-21
申请人： VIRON THERAPEUTICS INC. , LUCAS, Alexandra, R.
发明人： LUCAS, Alexandra, R.
IPC分类号： A61K38/57
CPC分类号： A61K38/1709 , G01N33/573 , G01N2800/32
摘要： The present invention features methods of treating a patient receiving a cardiac stent implant including the steps of: (i) monitoring the circulating level of TnI or CK-MB in the patient; and (ii) administering SERP-1 to the patient in an amount sufficient to prevent the circulating level of TnI or CK-MB from exceeding a specified threshold for the first 24 hours following implantation of the stent in the patient. The invention further features methods of treating a patient receiving a cardiac stent implant including the steps of: (i) monitoring the circulating level of TnI or CK-MB in the patient; and (ii) administering SERP-1 to the patient in an amount sufficient to achieve an exposure of SERP- 1 of at least a specified value during the first 24 hours following implantation of the stent in the patient. The invention additionally features methods of treating a patient receiving a cardiac stent implant including the steps of: (i) monitoring the circulating level of TnI or CK-MB in the patient; and (ii) administering SERP-1 to the patient within 24 hours of implantation of the stent in the patient.
摘要翻译：本发明的特征在于治疗接受心脏支架植入物的患者的方法，包括以下步骤：（i）监测患者中TnI或CK-MB的循环水平; 和（ii）以足以防止TnI或CK-MB的循环水平在患者植入支架后的前24小时超过规定阈值的量向患者施用SERP-1。本发明还涉及治疗接受心脏支架植入物的患者的方法，包括以下步骤：（i）监测患者中TnI或CK-MB的循环水平; 和（ii）在患者植入支架后的前24小时内以足以实现SERP-1暴露至少一定值的剂量向患者施用SERP-1。本发明另外具有治疗接受心脏支架植入物的患者的方法，包括以下步骤：（i）监测患者中TnI或CK-MB的循环水平; 和（ii）在患者体内植入支架的24小时内向患者施用SERP-1。

5. 发明申请

WO0231115A3 NUCLEIC ACID MOLECULES AND POLYPEPTIDES FOR IMMUNE MODULATION 审中-公开
标题翻译：核酸分子和多肽用于免疫调节
公开(公告)号：WO0231115A3
公开(公告)日：2003-02-13
申请号：PCT/US0132136
申请日：2001-10-11
申请人： VIRON THERAPEUTICS INC , MCFADDEN GRANT , ESSANI KARIM
发明人： MCFADDEN GRANT , ESSANI KARIM
IPC分类号： A01K67/027 , A61K38/00 , A61K39/275 , A61P1/04 , A61P1/16 , A61P3/10 , A61P5/16 , A61P7/00 , A61P7/06 , A61P7/08 , A61P9/10 , A61P11/00 , A61P11/02 , A61P11/06 , A61P13/12 , A61P15/06 , A61P17/00 , A61P17/02 , A61P17/06 , A61P19/00 , A61P21/02 , A61P21/04 , A61P25/00 , A61P25/28 , A61P29/00 , A61P31/12 , A61P31/18 , A61P35/02 , A61P37/02 , A61P37/04 , A61P37/06 , A61P37/08 , A61P43/00 , C07K14/065 , C07K16/08 , C12N5/10 , C12N15/09 , C12Q1/02 , C12Q1/68 , G01N33/15 , G01N33/50 , G01N33/53 , G01N33/566 , G01N33/569
CPC分类号： C07K14/005 , A01K2217/05 , A01K2217/075 , A61K38/00 , C12N2710/24022
摘要： The invention provides gp38 polypeptides, which play a role in immunomodulation, nucleic acid molecules encoding these polypeptides, and therapeutic and diagnostic methods employing these polypeptides and nucleic acid molecules. The invention also provides methods for identifying compounds that modulate the biological activities of gp38 nucleic acid molecules and polypeptides, and therapeutic methods employing these compounds.
摘要翻译：本发明提供了在免疫调节中起作用的gp38多肽，编码这些多肽的核酸分子，以及使用这些多肽和核酸分子的治疗和诊断方法。本发明还提供鉴定调节gp38核酸分子和多肽的生物学活性的化合物的方法，以及使用这些化合物的治疗方法。

6. 发明申请

WO2007149566A2 VIRAL SEQUENCES AND USES THEREOF 审中-公开
标题翻译：病毒序列及其用途
公开(公告)号：WO2007149566A2
公开(公告)日：2007-12-27
申请号：PCT/US2007014593
申请日：2007-06-21
申请人： VIRON THERAPEUTICS INC , MCFADDEN GRANT D , LUCAS ALEXANDRA , BARRET JOHN W
发明人： MCFADDEN GRANT D , LUCAS ALEXANDRA , BARRET JOHN W
IPC分类号： A61K39/12
CPC分类号： A61K48/00 , A61K38/162 , C07K14/005 , C07K2319/02 , C07K2319/21 , C07K2319/41 , C12N2710/24022
摘要： The invention features polypeptide and polynucleotide sequences based on the 134R sequence. In some embodiments, these sequences include a heterologous signal sequence, such as the myxoma virus T7 signal sequence. The invention also features methods- for treating immunological disorders and neoplasms (e.g., cancer) using the polypeptides and nucleotides described herein. Finally, the invention features fusion proteins including the myxoma virus T7 signal sequence.
摘要翻译：本发明的特征在于基于134R序列的多肽和多核苷酸序列。在一些实施方案中，这些序列包括异源信号序列，例如粘液瘤病毒T7信号序列。本发明还特征在于使用本文所述的多肽和核苷酸治疗免疫疾病和赘生物（例如癌症）的方法。最后，本发明的特征是融合蛋白包括粘液瘤病毒T7信号序列。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式